Insmed Inc (Insmed) focuses on the development and commercialization of drugs that treat rare diseases. Its product candidates include treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH) and severe refractory asthma, Brensocatib for bronchiectasis and approved products, namely, ARIKAYCE (amikacin liposome inhalation suspension) for treating nontuberculous mycobacterial (NTM) lung infection caused by a group of mycobacteria, namely, mycobacterium avium complex (MAC). The company operates through one reportable segment, the development and commercialization of therapies for patients with rare diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Insmed is advancing TPIP, an investigational sustained-release inhaled treprostinil prodrug nanoparticle formulation. It is also advancing brensocatib for reducing the damaging effects of inflammatory diseases such as non-CF bronchiectasis by inhibiting DPP1. In FY2022, the company spent US$397.5 million on its R&D, which increased 45.7% YoY. As of December 2022, the company had more than 450 issued patents and pending patent applications in the US and other countries, which include more than 250 issued patents and pending patent applications related to the approved product, ARIKAYCE.